Company Overview of OSI Pharmaceuticals Inc.
OSI Pharmaceuticals Inc. offers oncology drug discovery and translational research services which includes discovery of molecular targeted therapies. The company offers Tarceva, which treats non-small cell lung cancer. It develops OSI-906, a small-molecule and dual kinase inhibitor of insulin-like growth factor-1 receptor and insulin receptor for lung and ovarian cancers. The company develops OSI-027, a mammalian target of rapamycin kinase inhibitor that inhibits the kinase activity associated with the TORC1 and TORC2 complexes of mTOR. The company was formerly known as Oncogene Science Inc. and changed its name to OSI Pharmaceuticals Inc. in October 1997. The company was founded in 1983 and...
1 Bioscience Park Drive
Farmingdale, NY 11735
Founded in 1983
Key Executives for OSI Pharmaceuticals Inc.
Executive Vice President and President of Pharmaceutical Business
Interim Head of Oncology Development
Senior Vice President of Research and Development Diabetes & Obestity
Vice President of Clinical Research
Compensation as of Fiscal Year 2014.
OSI Pharmaceuticals Inc. Key Developments
OSI Pharmaceuticals Inc. Lays Off 115 Local Employees
May 14 13
OSI Pharmaceuticals Inc. announced that it is shuttering its remaining facility in the Long Island region and laying off all 115 of its local employees. The company said that it was closing the facility, located on the campus of Farmingdale State College. Most employees were dismissed immediately; a handful will stay to close the labs over the next four months. The workers will receive severances and continue to be paid for 90 days in accordance with state law. The closure is part of a global consolidation at Astellas, which is also shuttering facilities in Silicon Valley and suburban Chicago, cutting a total of 200 jobs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries